← All trials
NCT04400682
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2020
- Primary completion
- Jun 5, 2020
- Completion date
- Jul 17, 2020
- First posted
- May 25, 2020
- Last posted
- May 25, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Novelfarma Ilaç San. ve Tic. Ltd. Sti.Lead sponsor
- Farmagen Ar-Ge Biyot. Ltd. StiOverall official - principal investigator
- Farmagen Ar-Ge Biyot. Ltd. StiStudy chair
- Farmagen Ar-Ge Biyot. Ltd. StiCollaborator
- Novagenix Bioanalytical Drug R&D CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.